These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8894104)

  • 1. Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2' replacement for the symmetry-based HIV protease inhibitors.
    Randad RS; Lubkowska L; Silva AM; Guerin DM; Gulnik SV; Yu B; Erickson JW
    Bioorg Med Chem; 1996 Sep; 4(9):1471-80. PubMed ID: 8894104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
    Yedidi RS; Maeda K; Fyvie WS; Steffey M; Davis DA; Palmer I; Aoki M; Kaufman JD; Stahl SJ; Garimella H; Das D; Wingfield PT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4920-7. PubMed ID: 23877703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
    Thompson SK; Murthy KH; Zhao B; Winborne E; Green DW; Fisher SM; DesJarlais RL; Tomaszek TA; Meek TD; Gleason JG
    J Med Chem; 1994 Sep; 37(19):3100-7. PubMed ID: 7932533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
    Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
    Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex.
    Oscarsson K; Lahmann M; Lindberg J; Kangasmetsä J; Unge T; Oscarson S; Hallberg A; Samuelsson B
    Bioorg Med Chem; 2003 Mar; 11(6):1107-15. PubMed ID: 12614898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
    Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
    Rusere LN; Lockbaum GJ; Lee SK; Henes M; Kosovrasti K; Spielvogel E; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
    J Med Chem; 2019 Sep; 62(17):8062-8079. PubMed ID: 31386368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
    Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptidic potent HIV-1 protease inhibitors.
    Prasad JV; Lunney EA; Para KS; Tummino PJ; Ferguson D; Hupe D; Domagala JM; Erickson JW
    Drug Des Discov; 1996 Apr; 13(3-4):15-28. PubMed ID: 8874041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new class of HIV-1 protease inhibitor: the crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere.
    Rutenber EE; McPhee F; Kaplan AP; Gallion SL; Hogan JC; Craik CS; Stroud RM
    Bioorg Med Chem; 1996 Sep; 4(9):1545-58. PubMed ID: 8894111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
    Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
    J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
    Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
    Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine.
    Abdel-Rahman HM; el-Koussi NA; Alkaramany GS; Youssef AF; Kiso Y
    Arch Pharm (Weinheim); 2004 Nov; 337(11):587-98. PubMed ID: 15540219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.
    Ghosh AK; Martyr CD; Kassekert LA; Nyalapatla PR; Steffey M; Agniswamy J; Wang YF; Weber IT; Amano M; Mitsuya H
    Org Biomol Chem; 2015 Dec; 13(48):11607-21. PubMed ID: 26462551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.